Emkay Global Financial Services has reiterated its BUY recommendation on Pine Labs with a target price of Rs225, implying a potential upside of 50% from the current market price of Rs150.
News in Focus


ICICI Securities has reiterated its BUY recommendation on Aadhar Housing Finance Ltd with a target price of Rs 625, implying an upside potential of nearly 29 percent from the current market price o

Motilal Oswal Financial Services has reiterated its BUY recommendation on Coforge with a target price of Rs 1,900, implying an upside potential of nearly 30% from the current market price of Rs 1,4

RateGain Travel Technologies has emerged as one of the most compelling growth stories within India's travel technology ecosystem, according to Anand Rathi.


Rodrygo transfer rumors have lasted because the football logic is stronger than the gossip cycle.
Main Regional Stories

The Indonesia national football team enters 2026 with heavier expectations, even after missing the expanded World Cup.

China's race to close the AI gap with the United States is no longer theoretical — it's a matter of months.

Mumbai-based brokerage Motilal Oswal Financial Services Ltd (MOFSL) has reiterated a BUY rating on Nuvama Wealth Management, setting a one-year price target of Rs 1,860 — implying 23% upside from the stock's current market price of Rs 1,510.

ICICI Securities, through its retail research arm ICICI Direct, has reaffirmed a Buy rating on City Union Bank (CITUNI), pegging a 12-month target price of Rs 240 a share against a current market price of Rs 204 — an implied upside of 18%.
The Mars Science Laboratory or Curiosity of the American space agency, NASA will soon touch down in Mars' Gale crater, the agency announced.
A team of researchers in the Us have claimed that they have detected universe-changing Higgs boson particle, which is also called 'God particle', soon after a similar claim was made by researchers at Cern Institute near Geneva, which runs the Large Hadron Collider.
Mustardseed yesterday traded with the negative node and settled -0.07% down at 29
Glenmark Pharmaceuticals SA has successfully completed Phase-I clinical trials of its new molecule, GRC 15300, which has been developed for treatment of neuropathic pain. GRC 15300 is a first in–class inhibitor for treatment of pain.








